{
    "relation": [
        [
            "Arms",
            "Experimental: TDENV-PIV alum4 4 \u00b5g TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days",
            "Experimental: TDENV-PIV AS03B 1 \u00b5g TDENV-PIV with AS03B adjuvant; 0.5 mL intramuscular injection at 0 and 28 days",
            "Placebo Comparator: Placebo Phosphate buffered saline; 0.5 mL intramuscular injection at 0 and 28 days",
            "Experimental: TDENV-PIV alum1 1 \u00b5g TDENV-PIV with Alum adjuvant; 0.5 mL intramuscular injection at 0 and 28 days",
            "Experimental: TDENV-PIV AS01E 1 \u00b5g TDENV-PIV with AS01E adjuvant; 0.5 mL intramuscular injection at 0 and 28 days"
        ],
        [
            "Assigned Interventions",
            "Biological: Biological/Vaccine: 4 \u00b5g TDENV-PIV with Alum adjuvant",
            "Biological: Biological/Vaccine: 1 \u00b5g TDENV-PIV with AS03B adjuvant",
            "Other: Phosphate buffered saline",
            "Biological: 1 \u00b5g TDENV-PIV with Alum adjuvant",
            "Biological: 1 \u00b5g TDENV-PIV with AS01E adjuvant"
        ]
    ],
    "pageTitle": "A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/NCT01702857",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042989018.48/warc/CC-MAIN-20150728002309-00289-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 875913563,
    "recordOffset": 875902185,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "December 2016 (Final data collection date for primary outcome measure) Estimated Primary Completion Date: December 2019 Estimated Study Completion Date: November 2012 Study Start Date: 100 Estimated Enrollment: \u2022 To evaluate the safety of various TDENV-PIV formulations from Month 14 through the end of the study (Visit 15) [\u00a0Time\u00a0Frame:\u00a0Up to the end of study (Month 37-39)\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0Yes\u00a0] Trivalent and tetravalent seropositivity rates Seropositivity rates for each DENV type Rate of fold increases in neutralizing antibody from Day 0 for each DENV type Geometric mean titers (GMTs) of neutralizing antibody titers to each DENV type Humoral Immunogenicity: Humoral immunogenicity to each of four DENV types of various TDENV-PIV formulations on Days 0, 7 and 28 and Months 7 and 13 [\u00a0Time\u00a0Frame:\u00a0Up to month 13\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Occurrence of any SAE from Day 0 to Month 13 Occurrence of serious adverse events (SAEs) related to study procedures from Month 14 to end of study (Month 37-39)",
    "textAfterTable": "\u00a0 Eligibility Ages Eligible for Study: \u00a0 20 Years to 39 Years Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 Yes Criteria Inclusion Criteria: Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, etc.) A male or female between 20 and 39 years of age (inclusive) at the time of consent Written informed consent obtained from the subject Healthy subjects as established by medical history and clinical examination before entering into the study Subject has lived in the Caribbean for more than 10 years Female subjects of non-childbearing potential (non-childbearing potential is defined as having either a current tubal ligation at least three months prior to enrollment, hysterectomy, ovariectomy, or is post-menopause). Female subjects of childbearing potential may be enrolled in the study, if the subject has: practiced adequate contraception for 30 days",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}